Caribou Biosciences @CaribouBio Twitter profile

Last Seen Profiles

@lwHQUXgE8EfTyXs

@akiko0924happy

@victorkj

@intrludeholiday

@icey60

@Yuyaryu_MHA

@ADRPONTNEUF

@AnaliticaLaLiga

@intel

@pen_pen_9999

@Brittbeast33

@ChaotixDragon

@LuciaMis2

@saya122783

@35TH612

@kyliansol

@TT2senang

@StwGendut

@stw_pdg

@maritt_es

@insomniacgames

@Putriaja1101234

@Parkjimin51906

@GimoraBiltmore

@BinaryUnicycle

@mabo6111

@Talisayah8

@ShingiMararike

@Eguraldia24

@Tumi_Koma

@yan_baru55

@bingdwenedwen

@erenerdemnet

@xdotgd

@Alex_Shin0

@Sujuwings_

Caribou Biosciences

@CaribouBio

4 years

Thrilled to announce that the @FDA has cleared Caribou’s first IND for a CRISPR #genome -edited off-the-shelf allogeneic anti-CD19 CAR-T #celltherapy candidate for patients with relapsed/refractory B cell non-Hodgkin #lymphoma . Read more here:

1

23

80

Caribou Biosciences

@CaribouBio

3 years

Excited to share that Caribou is now publicly listed on @nasdaq as $CRBU! We look forward to progressing our scientific innovations in chRDNA-edited allogeneic cell therapies to transform the lives of patients living with devastating diseases.

11

15

68

Caribou Biosciences

@CaribouBio

1 year

We are pleased to announce @pfizer has invested $25M in Caribou as part of the Pfizer Breakthrough Growth Initiative (PBGI), a program focused on funding promising clinical development programs of potential future strategic interest to Pfizer.

4

10

57

Caribou Biosciences

@CaribouBio

6 months

$CRBU is expanding clinical development of CB-010 into #autoimmunedisease . We have received IND clearance from the @US_FDA for CB-010 in lupus nephritis and extrarenal lupus. More details on the GALLOP Phase 1 trial here: #Lupus #autoimmune #CRISPR

2

8

52

Caribou Biosciences

@CaribouBio

1 year

We are proud to announce FDA clearance of the IND application for CB-012, our allogeneic anti-CLL-1 CAR-T cell therapy for r/r #AML . Read more about the CB-012 AMpLify Phase 1 trial here: #leukemia

0

13

51

Caribou Biosciences

@CaribouBio

3 years

Thrilled to announce that the first patient has been dosed in our phase 1 clinical trial to evaluate a differentiated #CRISPR -edited allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma. Learn more:

1

7

46

Caribou Biosciences

@CaribouBio

10 months

We are pleased to announce we have received feedback from the FDA following a Type B meeting for the CB-010 Phase 3 pivotal trial. Read today’s press release for full details:

1

2

45

Caribou Biosciences

@CaribouBio

8 months

Prior to evaluating CB-011 in the ongoing CaMMouflage clinical trial, the $CRBU team investigated the impact of our immune cloaking strategy in preclinical models. Read the full analysis here: #CRISPR

High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses...

Allogeneic CAR T–cell therapies are being developed for hematologic malignancies. The authors implement a Cas12a chRDNA platform to generate allogeneic immune-cloaked BCMA-specific CAR T cells with...

aacrjournals.org

1

10

41

Caribou Biosciences

@CaribouBio

2 years

Excited to announce we are scheduled to share positive initial data for our ANTLER Phase 1 #clinicaltrial of CB-010 at #EHA2022 , demonstrating a generally well tolerated safety profile & a 100% ORR & 80% CR in r/r B-NHL patients. Read more:

2

8

39

Caribou Biosciences

@CaribouBio

2 years

We’re excited to announce the U.S. #FDA has cleared our IND application for CB-011, our anti-BCMA #CARTcelltherapy with immune cloaking for r/r #multiplemyeloma and we look forward to initiating patient enrollment for the CaMMouflage trial in early 2023.

3

6

34

Caribou Biosciences

@CaribouBio

6 months

Our poster presentation from #AACR2024 featuring preclinical, IND-enabling data from CB-012, our allogeneic anti-CLL-1 #CART cell therapy for the treatment of relapsed or refractory acute myeloid #leukemia , is now available for viewing on our website:

0

3

32

Caribou Biosciences

@CaribouBio

1 year

We are excited to announce that data from the 16 patients enrolled in dose escalation for the CB-010 ANTLER trial rival that of approved autologous #CARTcelltherapies . Read more here:

2

4

32

Caribou Biosciences

@CaribouBio

7 months

Preclinical data from CB-012, our allogeneic anti-CLL-1 CAR-T #celltherapy for the treatment of relapsed or refractory acute myeloid #leukemia , will be presented at #AACR24 in San Diego. Read today’s press release for full details: $CRBU @AACR

2

4

31

Caribou Biosciences

@CaribouBio

2 years

We are excited to share additional data from our ANTLER Phase 1 #clinicaltrial today at #EHA2022 , showing CB-010 as the 1st allogeneic CAR-T #celltherapy to achieve a 100% CR rate as best response for all 6 patients. To learn more, watch our webcast here:

0

6

31

Caribou Biosciences

@CaribouBio

5 months

Today we announced two abstracts have been accepted at #ASCO24 . The event will feature an update on initial clinical data from dose expansion in ANTLER Phase 1 trial. Read today's release for more details: $CRBU #CellTherapy #CRISPR

2

4

31

Caribou Biosciences

@CaribouBio

4 years

Unbelievably proud of our co-founder, Jennifer Doudna, and colleague, @e__charpentier , for winning the @NobelPrize in #Chemistry for their cutting-edge development of the CRISPR-Cas9 #geneticediting method. Read more about the exciting news here:

1

9

30

Caribou Biosciences

@CaribouBio

4 years

We’re delighted to announce the completion of a $115M Series C financing to advance our next-generation #CRISPR technologies and allogenic cell therapies for #oncology .

0

6

29

Caribou Biosciences

@CaribouBio

4 months

Results from our ongoing ANTLER clinical trial indicate CB-010 with partial HLA matching has the potential to rival the efficacy and safety profile of approved autologous CAR-T cell therapies. Join us at 7pm CT for a live webcast and here for more details

2

1

29

Caribou Biosciences

@CaribouBio

9 months

What a successful 2023! Read today’s press release for what is in store for Caribou in 2024:

0

2

26

Caribou Biosciences

@CaribouBio

1 year

Our next-generation chRDNA genome-editing technology is the foundation for the development of differentiated allogeneic cell therapies. Learn more about chRDNA and our other technologies on our website #CRISPR #CellTherapies

0

5

26

Caribou Biosciences

@CaribouBio

5 months

In the past quarter, Caribou has announced an IND clearance for lupus and has made progress across our clinical pipeline of allogeneic CAR-T cell therapies. Read more about it in our first quarter 2024 financial results and business update: #CRISPR $CRBU

1

3

26

Caribou Biosciences

@CaribouBio

4 months

We will be hosting a KOL discussion of CB-010 ANTLER Phase 1 clinical trial data at #ASCO24 this Sunday at 7:00 pm CT. Full details on the webcast and upcoming investor conferences here: #CRISPR #CARTcelltherapy $CRBU

1

0

26

Caribou Biosciences

@CaribouBio

1 year

Today at the @AACR 2023 Annual Meeting, we presented preclinical data supporting evaluation of CB-012, our 3rd allogeneic CAR-T cell therapy program, for the treatment of adult patients with r/r #AML #AACR2023 #cartcelltherapy #CRISPR

0

2

26

Caribou Biosciences

@CaribouBio

3 years

Today our CEO, Rachel Haurwitz, PhD, is participating in the Cell & Gene Meeting on the Mesa discussing Caribou’s #chRDNA technology to enhance cell therapies for cancer. If attending, check out the presentation to learn about our technology: #CGMesa21

2

3

25

Caribou Biosciences

@CaribouBio

2 months

We are advancing four oncology and autoimmune disease clinical-stage programs through multiple clinical data milestones expected in 2024 and 2025. Learn more about our progress in our Q2 2024 financial results here: $CRBU #CRISPR #CARTcelltherapy

1

6

26

Caribou Biosciences

@CaribouBio

5 years

A wonderful piece by @Forbes on #CRISPR companies founded by former “30 under 30” winners featuring our president and CEO Rachel Haurwitz

Gene Hackers: The Young Biotech Entrepreneurs Looking To Make Billions By Editing Life Itself

Entrepreneurs are taking genetic-editing technology from the lab to the clinic with grand ambitions. But who owns the patents?

www.forbes.com

0

9

25

Caribou Biosciences

@CaribouBio

3 years

Excited to announce publication of our data in @molecularcell demonstrating high specificity genome editing w/our proprietary #chRDNA technology, reinforcing our commitment to develop unique allogeneic CAR-T cell therapies for hematologic malignancies.

0

6

21

Caribou Biosciences

@CaribouBio

10 months

Caribou Biosciences SVP of translational sciences and therapeutic discovery Enrique Zudaire, PhD, will present clinical results from the CB-010 trial at the 4th Annual #CRISPR 2.0 Conference in Boston, MA, tomorrow at 11:45 am ET.

1

4

24

Caribou Biosciences

@CaribouBio

1 year

Tomorrow at the Jefferies Cell and Genetic Medicine Summit, join $CBRU president and CEO Rachel Haurwitz, PhD, for a fireside chat at 8:00 am ET. Head to our website for a link to the live webcast and replay of the discussion:

1

25

Caribou Biosciences

@CaribouBio

2 years

More good news! CB-011 has received FastTrack designation from the #FDA . CB-011 is a clinical-stage off-the-shelf #CARTcell therapy for multiple #myeloma . $CRBU More details here:

0

5

23

Caribou Biosciences

@CaribouBio

3 years

🎉 Congratulations to our President and CEO, Rachel Haurwitz, on being named to the inaugural class of @Bloomberg ’s New Economy Catalysts amongst innovators focused on accelerating solutions. Learn about the #BloombergCatalysts & upcoming live event:

0

1

23

Caribou Biosciences

@CaribouBio

8 months

#WorldCancerDay is a day to bring increased awareness to cancer patients, their families, medical personnel, and the caretakers who fight this disease together. The Herd is working to advance potentially transformative allogeneic #CARTcelltherapies :

0

5

24

Caribou Biosciences

@CaribouBio

4 years

We are thrilled to announce a collaboration & multi-year license agreement for CAR-T cell products with @abbvie allowing for the potential to develop next-generation “off-the-shelf” cellular therapies to benefit a broader patient population. Read More:

1

3

24

Caribou Biosciences

@CaribouBio

5 months

Today is #AMLAwarenessDay . Caribou Biosciences is committed to improving treatment for #AML by developing an off-the-shelf CAR-T cell therapy for this devastating disease. Learn more about CB-012 here: #leukemia #CRISPR #CARTcelltherapy

0

1

23

Caribou Biosciences

@CaribouBio

7 months

2023 was a year of significant clinical progress for Caribou. We look forward to continuing this momentum in 2024. Read our fourth quarter and full year 2023 financial results here: #celltherapy #CRISPR $CRBU

0

3

23

Caribou Biosciences

@CaribouBio

9 months

We know why Paul Donohoue was instrumental in making Caribou what it is today, but do you? Paul recounts the invention of chRDNA genome editing with @medicine_maker in this month’s issue. Read the full piece here:

Interviewing Paul Donohoue: A Guiding RNA-DNA Light for CRISPR

Paul Donohoue tells the story of how Caribou Biosciences developed a hybrid RNA-DNA guide to increase Cas9 specificity.

themedicinemaker.com

0

6

23

Caribou Biosciences

@CaribouBio

10 months

Reporting from #ASH23 day 1 – we had an amazing start to this year’s meeting and look forward to speaking with even more of you tomorrow at booth number #2251 ! #CRISPR #CARTcelltherapy #hematology #myeloma #lymphoma @ASH_hematology

0

3

21

Caribou Biosciences

@CaribouBio

3 years

#DYK women make up 29% of the #STEM labor force? Women make up 55% of our team, 5 of 7 BOD & 3 of 6 executives on our leadership team are female. We are challenging the gender norms to #BreakTheBias for women in our schools, communities, & workplaces. #InternationalWomensDay

1

2

22

Caribou Biosciences

@CaribouBio

6 years

Our CEO, Rachel Haurwitz, and Caribou co-founder, Jennifer Doudna, have been featured amongst #female business leaders on @Inc ’s first #FemaleFounders 100 list and we could not be more proud! Check out the full list here:

These 16 Founders Can See the Future of Everything From Artificial Intelligence to Ice Cream

These entrepreneurs on Inc.'s Female Founders 100 are challenging the norms across industries.

www.inc.com

0

3

21

Caribou Biosciences

@CaribouBio

6 months

The Caribou team had a great time at #AACR2024 . Thanks to everyone who stopped by the poster. If you missed it, be sure to check it out here: #AACR24 #AML

Caribou Biosciences

@CaribouBio

6 months

Our poster presentation from #AACR2024 featuring preclinical, IND-enabling data from CB-012, our allogeneic anti-CLL-1 #CART cell therapy for the treatment of relapsed or refractory acute myeloid #leukemia , is now available for viewing on our website:

0

3

32

1

2

22

Caribou Biosciences

@CaribouBio

2 years

Learn why our CEO, Rachel Haurwitz, PhD, believes off-the-shelf cell therapy products should be the future of cancer therapeutics and how our next-generation CRISPR technology, chRDNA, can help make it a reality in this article by @VivRaper at @GENbio .

Genetic Engineering & Biotechnology News

@GENbio

2 years

#CRISPR #GeneEditing Critical to Delivering Off-the-Shelf #CellTherapy @CaribouBio has developed a gene-editing system that uses CRISPR hybrid RNA-DNA (chRDNA) guides to improve on traditional CRISPR Cas9 gene editing. Learn more:

1

7

0

7

21

Caribou Biosciences

@CaribouBio

1 year

#WorldCancerResearchDay is a day to magnify the need for increased research, resources, & public awareness for those impacted by cancer. The Herd supports cancer research by working to advance potentially transformative allogeneic #CARTcelltherapies for patients with #BloodCancer

3

21

Caribou Biosciences

@CaribouBio

3 years

Pleased to welcome Nancy Whiting as the newest member of our board of directors. Dr. Whiting brings over 17 years of biotechnology industry expertise in drug and portfolio development, as well as significant strategic leadership experience. Learn more:

1

19

Caribou Biosciences

@CaribouBio

3 years

We’re excited to share Caribou’s new website! Check it out here:

1

21

Caribou Biosciences

@CaribouBio

3 years

As we kick off #WomensHistoryMonth , we are so pleased to see our CEO, Rachel Haurwitz, PhD, featured in the @SFBusinessTimes series on Women Who Lead. We are committed to growing and fostering female presence in #STEM education and careers. Learn more:

Women Who Lead: The CRISPR connections

Inside Nobel laureate Jennifer Doudna’s effort to create an ecosystem of women scientists.

www.bizjournals.com

0

3

20

Caribou Biosciences

@CaribouBio

3 years

Our CEO, Rachel Haurwitz, PhD, will be presenting a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. Catch the live webcast or view in our archive for 30 days: #JPM22

2

0

20

Caribou Biosciences

@CaribouBio

7 years

In its “Rising Stars” series, @ozy featured our CEO Rachel Haurwitz as someone set to change #medicine , #agriculture & #biotechnology . Learn more about her journey from researcher to CEO & how Caribou is using #CRISPR to fight #cancer & more

0

6

20

Caribou Biosciences

@CaribouBio

11 months

The Caribou team will be presenting at the 4th Annual #CRISPR 2.0 Conference next week in Boston! Socorro Portella, MD, and Ashley Hammad, RN, will lead a workshop on Tuesday, Nov. 28 at 1 pm ET and Enrique Zudaire, PhD, will present on Thursday, Nov. 30 at 11:45 am ET. #CARTcell

0

1

20

Caribou Biosciences

@CaribouBio

1 year

Happy 11th birthday, Caribou! 2023 has been an incredibly exciting year so far. Here’s to many more as we develop transformative genome-edited allogeneic cell therapies for devastating human diseases.

0

4

20

Caribou Biosciences

@CaribouBio

3 years

Thanks @bradloncar for the chat on Caribou and what we’ve been up to!

Brad Loncar

@bradloncar

3 years

Talking allo CAR-T with Rachel Haurwitz of Caribou Biosciences. We discuss PD-1 knockout, cloaking, and the recent CRISPR patent ruling. #IO360NYC

11

21

144

1

20

Caribou Biosciences

@CaribouBio

1 year

#ICYMI – Caribou Biosciences recently announced positive clinical data from our phase 1 ANTLER trial. Learn more with last month’s @biospace piece about the announcement:

Caribou Scores Early CAR-T Lymphoma Win, Plans $125M Public Offering

In a Phase I trial, Caribou’s allogeneic CAR-T cell therapy candidate induced high rates of treatment response in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

www.biospace.com

0

2

20

Caribou Biosciences

@CaribouBio

2 years

The first patient has been dosed in the CaMMouflage Phase 1 trial evaluating CB-011 in patients with relapsed or refractory multiple #myeloma . CB-011 is second program from our allogeneic CAR-T cell therapy platform to advance into the clinic. $CRBU

0

4

20

Caribou Biosciences

@CaribouBio

3 years

We are honored to share that our CEO, Rachel Haurwitz, PhD, was selected as an all-time all-star in @ForbesUnder30 Hall of Fame 10th anniversary issue. Check out her feature along with the other incredible individuals who were selected: #ForbesUnder30

0

3

18

Caribou Biosciences

@CaribouBio

6 years

We're excited to share that @Forbes recognized our CEO, Rachel Haurwitz, and Caribou co-founder, Jennifer Doudna, among top female #tech leaders on their 2018 America's Top 50 Women in Tech list! Check it out here:

0

6

19

Caribou Biosciences

@CaribouBio

2 years

We are thrilled to receive #RMAT and Fast Track designations from the #FDA for CB-010, an off-the-shelf anti-CD19 #CARTcelltherapy ! More details here: $CRBU

0

5

19

Caribou Biosciences

@CaribouBio

2 years

We’re celebrating 10 years of Caribou Biosciences! In the last decade, we developed the chRDNA genome-editing platform and today we are advancing our pipeline of off-the-shelf CAR-T and CAR-NK #celltherapies . Stay tuned. This is just the beginning for Caribou!

0

19

Caribou Biosciences

@CaribouBio

3 years

Our CEO, Rachel Haurwitz, PhD, took part in @SFBusinessTimes Health + Biotech Forum: Future of Cell and Gene Therapy. Joined by Josh Lehrer of @GraphiteBio , they shared their insights on the future growth of #biotech in the Bay Area.Learn about what we do:

1

3

18

Caribou Biosciences

@CaribouBio

3 years

Delighted to welcome Ran Zheng as the newest member of our board of directors. She brings 25+ years of biotechnology industry leadership experience in biologics drug development with broad expertise in technical operations and manufacturing. Learn more:

0

18

Caribou Biosciences

@CaribouBio

2 years

Recognition of the Herd’s recent accomplishments continues with a shout-out to the CB-011 team for the incredible effort that went into achieving IND clearance for CB-011, our allogeneic CAR-T cell therapy for r/r #multiplemyeloma . Read more here:

0

2

18

Caribou Biosciences

@CaribouBio

7 months

. @Cancerdotnet estimates 35,730 new cases of #MultipleMyeloma were diagnosed in 2023, and the 5-year survival rate is approximately 58%. Caribou is dedicated to improving the current standard of care with a novel cell therapy approach. #MultipleMyelomaAwareness

0

1

18

Caribou Biosciences

@CaribouBio

3 years

Today our CEO, Rachel Haurwitz, PhD, is participating at the Chardan Virtual 5th Annual Genetic Medicines Conference discussing gene editing & next-generation technologies. Catch the live webcast on Oct 4 at 5pm ET or by archive for 30 days:

1

2

18

Caribou Biosciences

@CaribouBio

3 months

Happy Independence Day from the Caribou Biosciences team! The Herd will be taking both the 4th and 5th off to spend time with family and friends. We wish you a restful holiday.

1

18

Caribou Biosciences

@CaribouBio

3 years

Next week our CEO, Rachel Haurwitz, PhD, will participate in a panel discussion on Exploring the State of Play in Cell Therapy at @Citi ’s 16th Annual BioPharma Conference. Catch the live webcast Sept 9 at 10:40am ET or by archive for 30 days:

1

5

17

Caribou Biosciences

@CaribouBio

3 years

This summer, we had the pleasure of celebrating our ninth birthday. We’re thankful to have such talented and dedicated team members working to make a difference in the lives of patients. Can’t wait to see where this team will take us in the next nine years!

1

4

17

Caribou Biosciences

@CaribouBio

10 months

Tune in on Thursday, January 11, at 11:15 am PST for a company presentation by $CRBU president & CEO Rachel Haurwitz, PhD, at #JPM24 . A link to the webcast is on the events section of our website:

0

5

17

Caribou Biosciences

@CaribouBio

2 years

We could not be prouder that our President & CEO Rachel Haurwitz, Ph.D., was named one of @SFBusinessTimes 2022 Most Admired CEOs! Congratulations, Rachel! You continue to motivate and inspire #TheHerd to make a difference in patients’ lives. #SFBT #MostAdmiredCEOs #HerdImpact

2

18

Caribou Biosciences

@CaribouBio

2 months

Caribou Biosciences turns 12! Yesterday, members of #TheHerd gathered to celebrate Caribou’s birthday and reminisce on the incredible discoveries and clinical progress over the years. #HappyBirthday ! #strongertogether

2

1

18

Caribou Biosciences

@CaribouBio

11 months

Join us in congratulating Paul Donohoue, Caribou's associate director of platform discovery, for his selection as a Biocom California 2023 Life Science Catalyst Award winner! Congratulations and incredibly well-deserved! #CRISPR

Biocom California

@BiocomCA

11 months

We are pleased to announce this year's annual Life Science Catalyst Award recipients. 🏆 Join us in congratulating all 10 winners recognized for exceptional achievement and leadership in the California life science industry before the age of 40. Read more:

1

5

18

0

2

17

Caribou Biosciences

@CaribouBio

5 months

Our presentation from #ASGCT24 showing data on the use of Cas12a chRDNA for efficient genome editing in vivo is now available for viewing on our website: #CRISPR #geneediting

1

17

Caribou Biosciences

@CaribouBio

2 years

The ANTLER trial has advanced into dose expansion! Dose expansion will include second-line patients with large B cell #lymphoma (LBCL), making CB-010 the first allogeneic CAR-T cell therapy to be evaluated in a clinical trial in second-line patients. $CRBU

0

3

17

Caribou Biosciences

@CaribouBio

3 years

Our CEO, Rachel Haurwitz, PhD, delivered a keynote today on using #CRISPR -based editing for off-the-shelf immune cell therapies for hematologic and solid tumors at the #IO360 Summit.

1

16

Caribou Biosciences

@CaribouBio

7 years

In recognition of #InternationalWomensDay , we’re delighted to share our CEO Rachel Haurwitz’s well-deserved spot in the @SFBusinessTimes feature: “Women Who Lead in Life Sciences”. #iwd2018

Women who lead in life sciences

From 3D-printed human organs to microbial genes to cancer treatments, these executives and researchers could have a huge impact in the biotech industry.

www.bizjournals.com

0

3

17

Caribou Biosciences

@CaribouBio

4 months

Join us Monday at #ASCO24 for two poster presentations sharing updated data from our ongoing ANTLER trial and the clinical trial design and objectives for our AMpLify trial. Poster session details here: #CARTcelltherapy #CRISPR #lymphoma #AML

0

3

17

Caribou Biosciences

@CaribouBio

6 months

Caribou Biosciences will host an investor call this afternoon at 5:00 pm ET/ 2:00 pm PT to discuss our expansion into autoimmune disease and the GALLOP Phase 1 study design. A link to the webcast is available on the investor section of our website: $CRBU

1

2

15

Caribou Biosciences

@CaribouBio

5 years

We're excited to share that our president and CEO, Rachel Haurwitz, was named as one of @BiocomCA 's ten Annual Catalyst Award winners, recognizing leaders under 40 making an impact on CA's life science industry! Read more here:

0

1

16

Caribou Biosciences

@CaribouBio

1 year

President and CEO of Caribou Biosciences, Rachel Haurwitz, PhD, will participate on a panel tomorrow at the STAT Future Summit. Join Rachel at 1:35 pm ET to learn more about the future of CAR-T cell therapies. #STATFUTURE

STAT

@statnews

1 year

Join STAT at our Future Summit and watch our panel "The Future of CAR-T" Rachel Haurwitz, David Chang and Lynelle Hoch speak with STAT's @adamfeuerstein Register: #STATFuture

2

4

8

0

2

16

Caribou Biosciences

@CaribouBio

2 years

Paul Donohoue, our Platform Discovery Group Lead, will present tomorrow on versatile chRDNA editing for engineering immune and #stemcells at FASEB’s Genome Engineering Conference in Lisbon, Portugal. #GECSRC22

0

2

16

Caribou Biosciences

@CaribouBio

2 years

We are honored to have our #CEO Rachel Haurwitz, PhD, recognized by @SFBusinessTimes as one of the Bay Area’s life science leaders. Read more here:

1

16

Caribou Biosciences

@CaribouBio

5 months

There are approximately 320,000 patients with systemic #lupus erythematosus (SLE) in the US. At Caribou, we’re developing a #CARTcelltherapy that may improve treatment options for these types of devastating autoimmune diseases. #LupusAwarenessMonth #WorldLupusDay

3

0

16

Caribou Biosciences

@CaribouBio

3 months

Today we announced the appointment of Terri Laufer, MD, to our scientific advisory board. Welcome to #theHerd , Dr. Laufer! #Lupus

1

0

15

Caribou Biosciences

@CaribouBio

7 years

Thank you @techreview for including our CEO Rachel Haurwitz on your 2017 35 Innovators Under 35 list! #TR35 #CRISPR

0

3

15

Caribou Biosciences

@CaribouBio

8 months

At the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain, Dr. Edward J. Pearson of the Baylor Charles A. Sammons Cancer Center, will present a case study on a patient from the dose escalation portion of the CB-010 ANTLER Phase 1 trial.

0

14

Caribou Biosciences

@CaribouBio

2 years

We’re pleased to share that our preclinical abstract for CB-012, our allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (AML) has been accepted for a poster presentation at #AACR2023 . Read more here:

0

3

15

Caribou Biosciences

@CaribouBio

1 year

We believe the future of CAR-T cell therapy is off-the-shelf and development of CB-010 would not be possible without outstanding clinical sites like @MCWCancerCenter and the courageous patients participating in the ANTLER trial.

MCW Cancer Center

@MCWCancerCenter

1 year

In July, MCW #cancer researchers opened a phase 1 #ClinicalTrial to test CB-010 in adults with relapsed/refractory B cell non-Hodgkin #Lymphoma . The study is the first to test an ‘off-the-shelf’ CAR-T therapy in the second line setting: #TherapyThursday

0

1

5

0

5

15

Caribou Biosciences

@CaribouBio

3 months

What advancements have been made to made to reduce off-targeting editing? Caribou’s CSO Steve Kanner, PhD, provides insights on this panel discussion with @_CellandGene host Erin Harris:

4

1

15

Caribou Biosciences

@CaribouBio

1 year

$CRBU has appointed world-renowned hematologist and CAR-T cell therapy pioneer, Stephen Schuster, to our scientific advisory board!

0

2

15

Caribou Biosciences

@CaribouBio

2 years

Caribou is proud to be advancing allogeneic cell therapies that may help #CancelBloodCancer . This month we’ll #TurnItRed in honor of those impacted by #BloodCancers . #BloodCancerAwarenessMonth #FightBloodCancer

0

3

14

Caribou Biosciences

@CaribouBio

2 years

Keep an eye out for the Herd at #ASH22 as several members of our clinical, medical affairs and leadership teams will be on site! Grab them and ask about our clinical-stage allogeneic CAR-T cell therapies. #lymphoma #multiplemyeloma #ASH2022

1

3

14

Caribou Biosciences

@CaribouBio

3 years

Thank you @LifeSciLeader for this wonderful feature on our CEO, Rachel Haurwitz, PhD, and the exciting work that Caribou has done so far and what’s to come. Check out the piece:

Can Caribou Biosciences Top 2021?

In 2021, much of Rachel Haurwitz’ hard-earned on-the-job training over the past decade culminated in a series of significant milestones that will undoubtably help position Caribou Biosciences for...

www.lifescienceleader.com

0

1

13

Caribou Biosciences

@CaribouBio

2 years

Paul Donohoue, our Platform Discovery Group Lead, will present a poster on Caribou’s chRDNA platform today at the American Society of Gene & Cell Therapy’s 25th Annual Meeting. #ASGCT22

0

14

Caribou Biosciences

@CaribouBio

8 months

Today is International Day for Women and Girls in Science! Caribou is proud to have some incredible women in the Herd serving as role models for future generations of female scientists, RAs, patent attorneys, and regulatory specialists.

0

1

14

Caribou Biosciences

@CaribouBio

1 year

Our clinical and medical affairs teams will be attending the 2023 Lymphoma, Leukemia & Myeloma Congress in New York City next week. We hope to see you there! Head to the #LLM23 website for more details: #lymphoma #leukemia #myeloma

Lymphoma, Leukemia & Myeloma Congress

@llmcongress

1 year

The Accredited Education You're Looking For Is Here. Did you know? The #LLMCongress2023 has created a customizable agenda to meet the educational needs of all hematologist-oncologist. Choose from 16 educational sessions each with its own unique highlights. Which Tracks Will

0

1

2

1

13

Caribou Biosciences

@CaribouBio

3 years

We are pleased to welcome Syed Rizvi, MD, as our Chief Medical Officer. Dr. Rizvi brings >20 years of experience in all stages of drug development supporting approval & commercialization of autologous CAR-T cell cancer treatments. #WelcometotheHerd

1

14

Caribou Biosciences

@CaribouBio

1 year

Don’t miss our president and CEO Rachel Haurwitz, discuss current CRISPR trends with Rodolphe Barrangou and Kevin Davies at the @GENbio State of Biotech Summit tomorrow. Register for free using the link below.

Genetic Engineering & Biotechnology News

@GENbio

1 year

Join us TOMORROW for the virtual event of the year feat. Nobel Laureate Carolyn Bertozzi, Daphne Zohar, Rodolphe Barrangou, & more. And the best part? It's free! @CarolynBertozzi @daphnezohar @CRISPRchef @Cytiva

0

4

11

0

3

14

Caribou Biosciences

@CaribouBio

1 year

CB-010, an allogeneic anti-CD19 #CARTcell therapy, is genome edited to target CD19-positive B cell non-Hodgkin #lymphoma cancer cells, mitigate risk of graft-versus-host disease, and reduce T cell exhaustion.

0

1

14

Caribou Biosciences

@CaribouBio

8 months

Mark your calendar for $CRBU presentations at upcoming investor conferences! Read our press release for full details and webcast information:

1

14

Caribou Biosciences

@CaribouBio

2 years

Preclinical data demonstrating potent antitumor activity in #multiplemyeloma with CB-011, will be shared in a poster presentation at #Tandem23 today at 5:45 p.m. ET. The poster is available on the Caribou website here: @ASTCT @CIBMTR

0

2

14

Caribou Biosciences

@CaribouBio

7 years

Thank you to all who attended @CRISPRcon at @UCBerkeley !

0

2

14

Caribou Biosciences

@CaribouBio

11 months

We are excited to announce the appointment of Sundar Jagannath, MD, to our scientific advisory board. We welcome Dr. Jagannath and his insights as a renowned expert in the treatment of #multiplemyeloma .

0

3

14

Caribou Biosciences

@CaribouBio

8 years

Thrilled our co-founder Dr. Doudna received the 2017 Japan Prize for outstanding & original achievements #CRISPR

0

7

14